Lantox treatment of neurogenic dysfunction of the bladder
- Авторлар: Maksimov VA1, Salyukov RV1, Martov AG1, Borisik VI1, Salyukova Y.R1, Maximov VA1, Salyukov RV1, Martov AG1, Borisik VI1, Salyukova Y.R1
-
Мекемелер:
- Шығарылым: № 5 (2010)
- Беттер: 53-56
- Бөлім: Articles
- URL: https://journals.eco-vector.com/1728-2985/article/view/277792
- ID: 277792
Дәйексөз келтіру
Толық мәтін
Аннотация
Авторлар туралы
V Maksimov
R Salyukov
A Martov
V Borisik
Yu Salyukova
V Maximov
R Salyukov
A Martov
V Borisik
Yu Salyukova
Әдебиет тізімі
- Шварц П. Г. Побочные эффекты антихолинергических средств, применяемых при лечении нейрогенных нарушений мочеиспускания. Фарматека 2005; 16: 65-71.
- Coffield J. A., Simpson L. L. The site and mechanism of action of botulinum neurotoxin. In: Jankovic J., Hallet M. ed. Therapy with botulinum toxin. New York: Marcel Dekker; 1994. 3-13.
- Орлова О. Р., Яхно Н. Н. Применение ботокса (токсина ботулизма типа А) в клинической практике. М.; 2001.
- Perkash I. Efficacy and safety of terazosin to improve voiding in spinal cord injury patients. J. Spinal Cord. Med. 1995; 18(4): 236-239.
- Chancellor M. B., Erhard M. J., Rivas D. A. Clinical effect of alpha-1 antagonism by terazosin on external and internal urinary sphincter function. J. Am. Paraplegia Soc. 1993; 16(4): 207-214.
- Abrams P., Freeman R., Anderstrom C., Mattiasson A. Tolterodine, a new antimuscarinic agent: as effective but better tolerated than oxybutynin in patients with an overactive bladder. Br. J. Urol. 1998; 81(6): 801-810.
- Drutz H. P., Appell R. A., Gleason D. et al. Clinical efficacy and safety of tolterodine compared to oxybutynine and placebo in patients with overactive bladder. Int. Urogynecol. J. Pelvic Floor Dysfunct. 1999; 10(5): 283-289.
- Appell R. A. Clinical efficacy and safety of tolterodine in the treatment of overactive bladder: a pooled analysis. Urology 1997; 50(6A, Suppl.): 90-96; [Discuss.: 97-99].
- Abrams P., Larsson G., Chapple C., Wein A. J. Factors involved in the success of antimuscarinic treatment. Br. J. Urol. Int. 1999; 83 (Suppl. 2): 42-47.
- Dykstra D. D., Sidi A. A., Scott A. B. et al. Effects of botulinum-A toxin on detrusor-sphincter dyssynergia in spinal cord injury patients. J. Urol. (Baltimore) 1988; 139(5): 919-922.
- Kreder K., Mayne C., Jonas U. Long-term safety, tolerability and efficacy of extended-release tolterodine in the treatment of overactive bladder. Eur. Urol. 2002; 41(6): 588-595.
- Schurch B. Botulinum-A toxin in spinal cord injury. Arch. Phys. Med. Rehabil. 1998; 79(11): 1481.